236 related articles for article (PubMed ID: 26048780)
21. Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON(®)-TB Gold (+) Kenyan adults without evidence of tuberculosis.
Walsh DS; Owira V; Polhemus M; Otieno L; Andagalu B; Ogutu B; Waitumbi J; Hawkridge A; Shepherd B; Pau MG; Sadoff J; Douoguih M; McClain JB;
Vaccine; 2016 May; 34(21):2430-2436. PubMed ID: 27026148
[TBL] [Abstract][Full Text] [Related]
22. A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area.
Hussein J; Zewdie M; Yamuah L; Bedru A; Abebe M; Dagnew AF; Chanyalew M; Yohannes AG; Ahmed J; Engers H; Doherty TM; Bang P; Kromann I; Hoff ST; Aseffa A
Trials; 2018 Jan; 19(1):24. PubMed ID: 29321075
[TBL] [Abstract][Full Text] [Related]
23. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
Satti I; Meyer J; Harris SA; Manjaly Thomas ZR; Griffiths K; Antrobus RD; Rowland R; Ramon RL; Smith M; Sheehan S; Bettinson H; McShane H
Lancet Infect Dis; 2014 Oct; 14(10):939-46. PubMed ID: 25151225
[TBL] [Abstract][Full Text] [Related]
24. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
Scriba TJ; Tameris M; Mansoor N; Smit E; van der Merwe L; Mauff K; Hughes EJ; Moyo S; Brittain N; Lawrie A; Mulenga H; de Kock M; Gelderbloem S; Veldsman A; Hatherill M; Geldenhuys H; Hill AV; Hussey GD; Mahomed H; Hanekom WA; McShane H
J Infect Dis; 2011 Jun; 203(12):1832-43. PubMed ID: 21606542
[TBL] [Abstract][Full Text] [Related]
25. Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial.
van Zyl-Smit RN; Esmail A; Bateman ME; Dawson R; Goldin J; van Rikxoort E; Douoguih M; Pau MG; Sadoff JC; McClain JB; Snowden MA; Benko J; Hokey DA; Rutkowski KT; Graves A; Shepherd B; Ishmukhamedov S; Kagina BMN; Abel B; Hanekom WA; Scriba TJ; Bateman ED
Am J Respir Crit Care Med; 2017 May; 195(9):1171-1180. PubMed ID: 28060545
[TBL] [Abstract][Full Text] [Related]
26. Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4+ T Cells.
Lenz N; Schindler T; Kagina BM; Zhang JD; Lukindo T; Mpina M; Bang P; Kromann I; Hoff ST; Andersen P; Reither K; Churchyard GJ; Certa U; Daubenberger CA
Clin Vaccine Immunol; 2015 Jul; 22(7):688-96. PubMed ID: 25924764
[TBL] [Abstract][Full Text] [Related]
27. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity.
Hoft DF; Blazevic A; Stanley J; Landry B; Sizemore D; Kpamegan E; Gearhart J; Scott A; Kik S; Pau MG; Goudsmit J; McClain JB; Sadoff J
Vaccine; 2012 Mar; 30(12):2098-108. PubMed ID: 22296955
[TBL] [Abstract][Full Text] [Related]
28. CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.
Elvang T; Christensen JP; Billeskov R; Thi Kim Thanh Hoang T; Holst P; Thomsen AR; Andersen P; Dietrich J
PLoS One; 2009; 4(4):e5139. PubMed ID: 19357780
[TBL] [Abstract][Full Text] [Related]
29. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers.
van Dissel JT; Arend SM; Prins C; Bang P; Tingskov PN; Lingnau K; Nouta J; Klein MR; Rosenkrands I; Ottenhoff TH; Kromann I; Doherty TM; Andersen P
Vaccine; 2010 Apr; 28(20):3571-81. PubMed ID: 20226890
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.
Tameris MD; Hatherill M; Landry BS; Scriba TJ; Snowden MA; Lockhart S; Shea JE; McClain JB; Hussey GD; Hanekom WA; Mahomed H; McShane H;
Lancet; 2013 Mar; 381(9871):1021-8. PubMed ID: 23391465
[TBL] [Abstract][Full Text] [Related]
31. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.
Abel B; Tameris M; Mansoor N; Gelderbloem S; Hughes J; Abrahams D; Makhethe L; Erasmus M; de Kock M; van der Merwe L; Hawkridge A; Veldsman A; Hatherill M; Schirru G; Pau MG; Hendriks J; Weverling GJ; Goudsmit J; Sizemore D; McClain JB; Goetz M; Gearhart J; Mahomed H; Hussey GD; Sadoff JC; Hanekom WA
Am J Respir Crit Care Med; 2010 Jun; 181(12):1407-17. PubMed ID: 20167847
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901.
von Reyn CF; Lahey T; Arbeit RD; Landry B; Kailani L; Adams LV; Haynes BC; Mackenzie T; Wieland-Alter W; Connor RI; Tvaroha S; Hokey DA; Ginsberg AM; Waddell R
PLoS One; 2017; 12(5):e0175215. PubMed ID: 28498853
[TBL] [Abstract][Full Text] [Related]
33. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.
Spertini F; Audran R; Chakour R; Karoui O; Steiner-Monard V; Thierry AC; Mayor CE; Rettby N; Jaton K; Vallotton L; Lazor-Blanchet C; Doce J; Puentes E; Marinova D; Aguilo N; Martin C
Lancet Respir Med; 2015 Dec; 3(12):953-62. PubMed ID: 26598141
[TBL] [Abstract][Full Text] [Related]
34. A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.
Sheehan S; Harris SA; Satti I; Hokey DA; Dheenadhayalan V; Stockdale L; Manjaly Thomas ZR; Minhinnick A; Wilkie M; Vermaak S; Meyer J; O'Shea MK; Pau MG; Versteege I; Douoguih M; Hendriks J; Sadoff J; Landry B; Moss P; McShane H
PLoS One; 2015; 10(11):e0141687. PubMed ID: 26529238
[TBL] [Abstract][Full Text] [Related]
35. Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A.
Tanner R; Kakalacheva K; Miller E; Pathan AA; Chalk R; Sander CR; Scriba T; Tameris M; Hawkridge T; Mahomed H; Hussey G; Hanekom W; Checkley A; McShane H; Fletcher HA
BMC Infect Dis; 2014 Dec; 14():660. PubMed ID: 25466778
[TBL] [Abstract][Full Text] [Related]
36. Tuberculosis vaccine candidate: Characterization of H4-IC31 formulation and H4 antigen conformation.
Deshmukh SS; Magcalas FW; Kalbfleisch KN; Carpick BW; Kirkitadze MD
J Pharm Biomed Anal; 2018 Aug; 157():235-243. PubMed ID: 29866391
[TBL] [Abstract][Full Text] [Related]
37. Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial.
Kumarasamy N; Poongulali S; Beulah FE; Akite EJ; Ayuk LN; Bollaerts A; Demoitié MA; Jongert E; Ofori-Anyinam O; Van Der Meeren O
Medicine (Baltimore); 2018 Nov; 97(45):e13120. PubMed ID: 30407329
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and protective efficacy of novel Mycobacterium tuberculosis antigens.
Derrick SC; Yabe IM; Yang A; Kolibab K; Hollingsworth B; Kurtz SL; Morris S
Vaccine; 2013 Sep; 31(41):4641-6. PubMed ID: 23906890
[TBL] [Abstract][Full Text] [Related]
39. Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A.
Harris SA; Satti I; Matsumiya M; Stockdale L; Chomka A; Tanner R; O'Shea MK; Manjaly Thomas ZR; Tameris M; Mahomed H; Scriba TJ; Hanekom WA; Fletcher HA; McShane H
Clin Vaccine Immunol; 2014 Jul; 21(7):1005-11. PubMed ID: 24828094
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study.
Gillard P; Yang PC; Danilovits M; Su WJ; Cheng SL; Pehme L; Bollaerts A; Jongert E; Moris P; Ofori-Anyinam O; Demoitié MA; Castro M
Tuberculosis (Edinb); 2016 Sep; 100():118-127. PubMed ID: 27553419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
